Takeda Pharmaceutical Company Limited

Takahiko Taniguchi

Masato Yoshikawa

Jun Kunitomo

Shinji Nakamura

Masaki Seto

Tomoaki Hasui

Eiji Honda

Makoto Fushimi

Keisuke Imamura

Kasei Miura

Makoto Kamata

Shigekazu Sasaki

Satoshi Mikami

Izumi Nomura

Tomoko Ashizawa

Haruhi Kamisaki

Shinkichi Suzuki

John Frederick Quinn

Masanori Kawasaki

Keiji Kubo

Masaki Kawamura

Haruhi Ando

Hiroshi Banno

Joseph Raker

Shotaro Miura

Kazuaki Takami

Takenori Hitaka

Yoshiyuki Fukase

Koichiro Fukuda

Yoshihiro Banno

Masahiro Kamaura

Christer Halldin

Tomoyasu Ishikawa

Hironori Kokubo

Kenichi Miyata

Akira Kawada

Osamu Kubo

Fatoumata Camara

Yi Wang

Mamoru Tobisu

Masaharu Nakayama

Vladimir Stepanov

Akihiro Takano

Kawasaki Masanori

The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

Nitrogenated heterocyclic compound

Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

Heterocyclic compound

The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of PDE10A in mammals. The compound of the present invention is represented by the formula (I): wherein each symbols are as defined in the specification. 

Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (PDE10A) in mammals

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I): 

Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders

Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I): 

Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors

A compound having PDE inhibitory represented by formula (1), W-W(1), wherein (i) Wis and Wis (ii) Wis and Wis or (iii) Wis and Wis or a pharmaceutically acceptable salt thereof; and a method of treating or preventing schizophrenia.

Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors

The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification, or a salt thereof, a prodrug of the compound or a salt thereof, a medicament containing the compound or a salt thereof, the medicament which is a phosphodiesterase 10A inhibitor, and a medicament which is for preventing or treating schizophrenia.

The present invention provides a compound having a superior PDE10A inhibitory action and use thereof. The compound is a compound represented by the following formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

Condensed heterocyclic compound

The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound represented by the formula (1'): wherein, Ring A&#x2032; represents an optionally substituted pyridine ring, an optionally substituted pyridazine ring, a pyrimidine ring, or 10 a pyrazine ring, R1&#x2032; represents (1) wherein, Rrepresents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2 represents a bond, &#x2014;S&#x2014;, -0-, &#x2014;CO&#x2014;, an optionally substituted methylene group, or &#x2014;NR&#x2014; (Rrepresents a hydrogen atom, or an optionally substituted Calkyl group), and Ring Brepresents an optionally further substituted 6- to 10-membered aromatic hydrocarbon ring, or an optionally further substituted 5- to 10-membered aromatic heterocyclic ring, or alternatively, L&#x2032; and Rmay be taken together to form an optionally substituted bicyclic or tricyclic fused heterocyclic group, or (2), wherein, Rrepresents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring Brepresents an optionally substituted benzene ring, an optionally substituted pyridine ring, an optionally substituted pyrimidine ring, an optionally substituted pyrazine ring, or an optionally substituted pyridazine ring, Ring D&#x2032; represents an optionally further substituted 5- or 6-membered ring, Rrepresents a hydrogen atom, or a substituent, X&#x2032; represents &#x2550;N&#x2014; or &#x2550;CR&#x2014;(Rrepresents a hydrogen atom, or a substituent), - - - - - represents that Rand Rmay form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when.X&#x2032; is &#x2550;CR, or a salt thereof.

Fused heterocyclic compounds

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.

Provided is a compound having a PDE10A inhibitory action, and useful as a medicament for the prophylaxis or treatment of mental diseases such as schizophrenia and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

Fused heterocyclic ring compound

Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors

Growing community of inventors

Kanagawa, Japan

Takahiko Taniguchi